Recent Finacing
Recent Raise
PhotonPharma develops Innocell™, a personalized immunotherapy for advanced ovarian and solid tumors, with FDA clearance to start Phase I clinical development expected to enroll in Q4 2024.
Focus Areas
Total Raised
Funding round
See the team members at Photonpharma.
